Meet Professor Pola Goldberg Oppenheimer, a trailblazer in Micro-Engineering and Bio-Nanotechnology at the University of Birmingham. Her pioneering work is not just a leap but a quantum jump in the complex world of nanostructured materials and their applications in healthcare technologies.
With a stellar academic lineage from the University of Cambridge and a host of accolades, including the prestigious Royal Academy of Engineering Fellowship, Professor Oppenheimer is redefining the boundaries of applied science. Her radical invention of a smart nanoplasmonic-optofluidic device has significantly impacted the diagnosis of Traumatic Brain Injury (TBI), a leading cause of morbidity worldwide.
In a landmark study, her team at the University of Birmingham has turned its focus to that critical yet often overlooked medical challenge: TBIs. Leveraging the power of Raman spectroscopy and neuroretinal fundus imaging, their research aims to revolutionize the way TBIs are detected, particularly in their elusive early stages. Considering the staggering global impact of TBIs – with over 135 million affected individuals and a troubling mortality rate as reflected in the 200,000 TBI-related deaths in India every year – this research is not just timely but urgent.
In the email interview with Neo Science Hub, Professor Oppenheimer delves deeper into her team’s research and to understand what advancements are on the horizon for early TBI detection. Her insights offer a glimpse into the future of medical diagnostics, where innovation and practicality meet to save lives.
1.What are the existing obstacles in the early detection of Traumatic Brain Injury (TBI) in patients?
Traumatic Brain Injury (TBI) stands as a significant global health challenge, anticipated to be the third-largest cause of neurological disability and death by 2030, according to WHO projections. In the UK, where a head injury admission occurs approximately every 3 minutes, the annual toll is staggering, with 2 million people grappling with long-term disabilities. This not only burdens healthcare systems but also exacts a considerable economic toll.
The urgency to address TBI is underscored by the difficulty in rapid point-of-care diagnosis, leading to suboptimal patient management and increased risks of cognitive or physical impairment. With millions affected annually, TBI becomes a pressing public health concern.
Existing diagnostic methods fall short—either due to the need for large equipment, extended waiting times, invasiveness, or insufficient sensitivity and timeliness. Notably, there is a glaring absence of point-of-care technology for TBI. The imperative for new technologies is clear: to enable timely intervention through rapid and accurate diagnostics at the point of care.
2. How does this particular system enhance the current clinical methods available?
Our portable device represents a transformative advancement in traumatic brain injury (TBI) detection, especially in point-of-care (PoC) scenarios where immediate expert evaluation or radiological investigations are unavailable, such as roadside, pitch-side, or austere combat environments.
This PoC technology addresses the current challenges of mis-triage, saving both healthcare costs and improving outcomes by guiding early management. Designed for on-site use by medical professionals and ambulance crews, our spectroscopic technique ensures timely and cost-effective diagnosis and triage. The non-invasive, cost-effective approach in the early clinical phase allows for personalized medicine and management improvements, alleviating strain on the healthcare system.
Given TBI’s complications and the prolonged impact on patients, rapid diagnosis is crucial. Cost savings are proportional to the reduction in mis-triage rates during pre-hospital assessment, where existing tools demonstrate suboptimal sensitivities. Our device complements, rather than replaces, the need for CT scans in well-resourced healthcare systems, enabling timely management of occult TBIs and facilitating correct triage.
The system’s potential to replace unnecessary CT scans in some cases aligns with the goal of reducing financial burdens on families. Beyond bench-top prototyping, the scalable manufacturing of this portable device ensures widespread deployment, offering a cost-effective, portable, and user-friendly medical solution for both pre-hospital and hospital settings. The socioeconomic impact of TBI, coupled with the device’s anticipated cost-effectiveness, positions it as a valuable addition to medical equipment lists and capabilities.
3. What makes Raman spectroscopy a suitable solution for this issue?
Our device, leveraging Raman spectroscopy, presents a groundbreaking solution for early traumatic brain injury (TBI) diagnosis by directly assessing real-time acute distress changes in living neuro-retinal and optic nerve tissue. What sets Raman spectroscopy apart is its ability to enable direct and non-invasive interrogation of the central nervous system (CNS). The use of Raman spectroscopy to read optical signals from the retina/optic nerve ensures a non-contact assessment with virtually instantaneous results—a distinctive feature not found in directly comparable technologies.
Measuring changes in optical biomarkers via Raman spectroscopy holds a significant advantage over other techniques, allowing quick and noninvasive assessment. The compact design and minimal energy requirements of our Raman spectrometer facilitate a non-invasive method for probing the posterior segment of the eye, enabling TBI detection at the point of care and real-time monitoring of injury evolution.
In the realm of optical techniques, Raman stands out for its rich and sensitive spectroscopic discrimination, providing unique molecular fingerprints through its spectra. The combination of Raman spectroscopy with fundus imaging for assessing the retina/optic nerve further enhances the non-contact and real-time aspects of the diagnostic process.
Our approach, utilizing Raman spectroscopy, not only offers a cost-effective solution but also introduces a handheld device for analyzing the neuroretina—an insightful window into brain biochemistry. This represents a significant stride toward non-invasive, rapid diagnostics of TBI at the point of care, marking a paradigm shift in addressing this critical medical challenge.
4. Is this system currently in use for patient care? If not, are there any future plans to implement it?
Currently, our focus lies in optimizing the prototype for clinical validation of Raman-fundus spectroscopy. The ongoing efforts involve engineering a user-friendly deployable device integrated with our artificial neural network algorithm. This algorithm facilitates automated interpretation of outputs without specialist support, swiftly classifying spectral data. To gauge its potential for real-time diagnosis, we are in the process of clinically evaluating the device’s usability in both healthy volunteers and patients.
Once we establish the device’s tolerability and usability, the next phase involves a first-in-human evaluation and a small-scale clinical trial. This progression marks a strategic roadmap toward translating our innovative solution from prototype refinement to practical implementation, ultimately aiming to enhance early traumatic brain injury diagnosis in a clinical setting.
5. What areas of research are still needed in this field?
The research in this space is multifaceted and encompasses several crucial dimensions. Firstly, the development of our bespoke artificial neural network algorithm, SKiNET (self-optimizing Kohonen index network), has laid the foundation for sophisticated multivariate analysis. Acting as a generic framework, SKiNET provides dimensionality reduction, feature extraction, and multiclass classification in a seamless interface. Its integration into the final device will serve as a decision support tool, automating the interpretation of Raman data and eliminating the need for specialist support, thereby significantly enhancing diagnostic speed and cost-effectiveness.
In ex vivo murine retina studies, we have successfully demonstrated the feasibility of Raman in differentiating traumatic brain injury (TBI) from healthy controls with high accuracy across various injury severities. This aligns with measurements from brain data, showcasing spectral changes associated with cardiolipin and metabolic distress.
Expanding our experiments to pig eyes using a 633nm excitation wavelength, we detected molecular fingerprints of TBI neuromarkers. The subsequent observation of clear separation between control and TBI groups using SKiNET further validates the potential of our approach.
We have progressed to develop a portable proof-of-concept Raman-fundus device capable of measuring signals in short timescales. This device, featuring a collimated beam and CE-marked Class I laser, measures Raman spectra from the optic nerve. Extensive animal studies on TBI identification, utilizing both laboratory-based and portable Raman, form the groundwork for the development of in vivo clinical measurements using a new portable eye-safe device.
Our current focus involves optimizing the prototype for clinical validation of Raman-fundus spectroscopy. This includes engineering a user-friendly deployable device integrated with SKiNET for automated interpretation of outputs. The ongoing clinical evaluation in healthy volunteers and patients aims to showcase the device’s potential for real-time diagnosis. The subsequent progression to a first-in-human evaluation and small-scale clinical trial represents the next crucial steps in bringing this innovative solution to practical clinical implementation.
6. Were there any unexpected findings in this research that would be interesting for our readers to know about?
The journey of this research has been a dynamic one, marked by both challenges and moments of revelation. The process of getting the integrated system to function has been characterized by ups and downs, bringing about surprises that mirror the intricate nature of scientific exploration. One of the notable surprises was the genuine excitement derived from successfully obtaining a signal from the brain through the eye—a testament to the unpredictability and thrilling nature of groundbreaking scientific inquiry.
-NSH
